Trials / Unknown
UnknownNCT05222633
Anti-VEGF in Real-world
Observation of Anti-vascular Endothelial Growth Factor Therapy in Exudative Age-related Macular Degeneration, Proliferative Diabetic Retinopathy, Macular Edema, and Choroidal Neovascularization.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Wenbin Wei · Academic / Other
- Sex
- All
- Age
- 35 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
Detailed description
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferative diabetic retinopathy / proliferative diabetic retinopathy, retinal vein occlusions related macular edema, and choroidal neovascularization secondary to multiple retinal diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-VEGF drugs. In the current study, the primary aim is to aim to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.
Conditions
- Neovascular Age-related Macular Edema
- Diabetic Macular Edema
- Choroidal Neovascular Membrane
- Non-proliferative Diabetic Retinopathy
- Retinal Vein Occlusion
- Proliferative Diabetic Retinopathy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | Ranibizumab 0.5mg/0.05ml intravitreal injection |
| DRUG | Aflibercept | Aflibercept 2.0mg/0.05ml intravitreal injection |
| DRUG | Conbercept | Conbercept 0.5mg/0.05ml intravitreal injection |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2023-01-01
- Completion
- 2023-05-01
- First posted
- 2022-02-03
- Last updated
- 2022-02-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05222633. Inclusion in this directory is not an endorsement.